Wandercraft, a global robotics company, announced the acquisition of Ekso Bionics from a subsidiary of ChronoScale Holdings Corporation. The acquisition combines Wandercraft’s expertise in advanced robotics and physical artificial intelligence and its presence in Europe, the Middle East, and Africa, with Ekso Bionics’ US presence, clinical experience, and commercial reach.
The combination creates a broader portfolio of medical exoskeletons spanning the continuum of care, from rehabilitation to everyday personal mobility, Wandercraft said. The complementary platforms hold US Food and Drug Administration clearances and CE marking from the European Union covering stroke, spinal cord injury, multiple sclerosis, and acquired brain injury.
“Ekso has spent two decades pioneering robotic technologies, advancing engineering and R&D, and building a robust body of clinical research and evidence that has earned the trust of clinicians and the people who rely on our products,” said Scott Davis, Ekso Bionics. “Joining Wandercraft represents an exciting next chapter, uniting two organizations with a shared commitment to mobility, rehabilitation, and innovation. Together, we can build on that trailblazing work and expand our ability to develop and deploy technologies that make a meaningful difference for more people.”
Financial terms of the acquisition were not disclosed.
